Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sosei Heptares

www.sosei.com

Latest From Sosei Heptares

Coronavirus Update: A Key Vaccine Partnership, Promising Treatments, And A Rocky First Quarter

A new COVID-19 vaccine dream team, updated trial results on remdesivir, and a rough first quarter for big pharma stocks. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, these three topics are among a selection of brief insights we’re bringing you on biopharma commercial activities.

Coronavirus COVID-19 Clinical Trials

Coronavirus Update: Moderna Scales Up Manufacturing, Sosei Looks To Structure-Based Design, Taking Stock Of India’s Lockdown

Moderna details plans on how it will make enough of its coronavirus vaccine, and Sosei is using structure-based design technology to target a SARS-CoV-2 non-strucural protein. Meanwhile, the industry in India faces up to lockdown. 

Coronavirus COVID-19 Companies

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.

Deals M & A

Sosei Heptares Bags Second GPCR Targets Deal In A Month, With Takeda

The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that modulate GPCR targets, initially in GI.

Commercial Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gynecological, Urological
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Sosei Group Corp.
  • Sosei Co. Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Sosei Heptares
  • Senior Management
  • Shinichi Tamura, Chmn., Pres. & CEO
    Chris Cargill, EVP, CFO
    James Taylor, SVP, Bus. Dev.
    Malcolm Weir, EVP, Chief R&D Officer
    Tim Tasker, MD, EVP, CMO
    Barry Kenny, PhD, CBO, Bus. Dev.
  • Contact Info
  • Sosei Heptares
    Phone: (81) 3 5210 3290
    PMO Hanzomon 11F
    2-1 Kojimachi
    Tokyo, 102-0083
    Japan
UsernamePublicRestriction

Register